The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01F | Monoclonal antibodies and antibody drug conjugates | |
4
|
L01FD | HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors | |
5
|
L01FD01 | Trastuzumab |
| Active Ingredient |
|---|
|
Trastuzumab is a recombinant humanised IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). Τrastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumour cells that overexpress HER2. |
| Document | Type | Information Source | |
|---|---|---|---|
| HERCESSI Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| ONTRUZANT Powder for concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.